 |
 |

Chemotherapy for OligodendrogliomaProgress Report
J. Gregory Cairncross, MD;
David R. Macdonald, MD
Arch Neurol. 1991;48(2):225-227.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
Six years ago, we began to notice that recurrent oligodendrogliomas, tumors that had regrown after one or more surgeries and radiotherapy, responded to chemotherapy. These tumors were clinically aggressive, contrast-enhancing, histologically anaplastic, and relatively pure. We concluded, after eight consecutive responses (see reference 1 for response criteria),1 that anaplastic oligodendroglioma was a chemosensitive tumor.2 In this article, we review our experience with chemotherapy for this uncommon brain tumor.
Table 1 summarizes the results of treatment for "first" recurrence. We have treated 10 patients, all have responded; two completely and eight partially. Patient 1 responded to carmustine (BCNU), patient 4 to diaziquone (AZQ), the others to a drug combination (PCV) that included procarbazine, lomustine (CCNU), and vincristine.3 (Patient 5 failed to respond to fludarabine, patient 8 to diaziquone; both responded to PCV.) The median duration of response is 15 months (range, 8 to 36 months). All patients have
. . . [Full Text PDF of this Article]
Author Affiliations
From the Departments of Clinical Neurological Sciences and Oncology, University of Western Ontario, and the London Regional Cancer Centre, London, Ontario.
Footnotes
Accepted for publication September 20, 1990.
Reprint requests to London Regional Cancer Centre, 790 Commissioners Rd E, London, Ontario, Canada N6A 4L6 (Dr Cairncross).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|